Earnings Prediction Review: Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)

Share

A number of other research firms also recently commented on ALXN.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) topped its 52-week high price of $162 on April 22, 2016 and 52-Week Low Price of $109.12 on Dec 13, 2016.

Currently, Alexion has a Zacks Rank #3 (Hold), but that could definitely change following the company's earnings report which was just released.

Soliris, approved for rare blood disorders paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, generated quarterly sales of $749 million, underwhelming consensus estimates of $756 million, according to Barclays. Seven investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. Alexion Pharmaceuticals now has a consensus rating of "Buy" and an average target price of $172.91.

Gold prices gain in Asia as Dudley views on rates shrugegd off
Bears' next near-term downside price breakout objective is pushing prices below solid technical support at $1,200.00. Yellen's comments boosted appetite for assets perceived as higher risk, like equities, as well as the dollar.

"Alexion Pharmaceuticals, Inc. (ALXN) Stake Boosted by Aviva PLC" was published by Community Financial News and is owned by of Community Financial News. The stock's market capitalization is 29.00B, it has a 52-week low of 109.12 and a 52-week high of 162.00. The stock's 50 day moving average price is $131.14 and its 200 day moving average price is $127.06.

Non-GAAP diluted earning per share (EPS) for the fourth quarter was $1.26 per share, compared to $1.04 per share past year. The biopharmaceutical company reported $1.23 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $1.04 by $0.19. Alexion Pharmaceuticals had a return on equity of 10.58% and a net margin of 12.46%. The Next Year EPS growth is 19.7%, Long term annual growth estimate of 21.05%, Annual EPS growth past 5 years of 28.57 percent.

Price Target plays a critical role when it comes to the Analysis of a Stock. Analysts, on average, forecast Alexion Pharmaceuticals, Inc.to earn $1.31 per share (EPS) on revenue of $840.34M. Also, Director Leonard Bell sold 40,065 shares of Alexion Pharmaceuticals stock in a transaction on Monday, January 9th. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The shares were sold at an average price of $130.00, for a total value of $300,040.00.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) is now showing its ROA (Return on Assets) of 3.1%. The disclosure for this sale can be found here. The most recent short interest data show 2% of the company's stock are short sold. IFM Investors Pty Ltd bought a new stake in shares of Alexion Pharmaceuticals during the fourth quarter valued at about $386,000. News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals, Inc. with MarketBeat.com's FREE daily email newsletter.

Gatland keeping an open mind over Lions squad
The wily New Zealander is unsurprisingly keeping his cards close to his chest over selection after two rounds of the Six Nations. New Zealand Rugby says 75 percent of the tickets for the ten game tour have been sold.

The company's CEO and CFO resigned in December, amidst speculation that the board had lost confidence in them, a month after Alexion said it was investigating allegations related to sales practices of its costly medicine Soliris. California State Teachers Retirement System boosted its position in Alexion Pharmaceuticals by 0.4% in the second quarter. Ltd. now owns 356,642 shares of the biopharmaceutical company's stock valued at $41,642,000 after buying an additional 6,770 shares during the last quarter.

While if we look at the Earnings Track Record, Alexion Pharmaceuticals, Inc.

Sales of Strensiq, which treats Hypophosphatasia, a rare genetic disorder characterized by the abnormal development of bones and teeth, were $71 million in the quarter, up from $12 million in the same quarter previous year. The number of shares now owned by investors are 224.94 mln. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment.

Apple Inc. (NASDAQ:AAPL) Becomes No. 1 Smartphone Seller in Q4
Samsung also had to fiercely compete with Huawei, Oppo, BBK and Gionee which all witnessed growth in their sales in this quarter. Oppo maintained its number one position in China, aided by high-performance, front facing cameras and fast charging smartphones.

Share